Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I/II Study of Azacitidine, Venetoclax and Pevonedistat in Adults With Newly Diagnosed Secondary or Therapy-Related AML

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03862157
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:15.192813+00:00
Published At
2026-03-11T00:00:00+00:00
Record Updated At
2026-03-11
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Acute Myeloid Leukemia", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Chronic Eosinophilic Leukemia, Not Otherwise Specified", "Chronic Myelomonocytic Leukemia", "Chronic Neutrophilic Leukemia", "Essential Thrombocythemia", "Myelodysplastic Syndrome", "Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Myeloid Neoplasm", "Myeloproliferative Neoplasm", "Myeloproliferative Neoplasm, Unclassifiable", "Overt Primary Myelofibrosis", "Polycythemia Vera", "Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase", "Prefibrotic/Early Primary Myelofibrosis"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-03-11"
protocolSection.identificationModule.nctId
"NCT03862157"
protocolSection.identificationModule.officialTitle
"A Phase I/II Study of Azacitidine, Venetoclax and Pevonedistat in Adults With Newly Diagnosed Secondary or Therapy-Related AML"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
  • Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative (protocolSection.conditionsModule.conditions)
  • Chronic Eosinophilic Leukemia, Not Otherwise Specified (protocolSection.conditionsModule.conditions)
  • Chronic Myelomonocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Chronic Neutrophilic Leukemia (protocolSection.conditionsModule.conditions)
  • Essential Thrombocythemia (protocolSection.conditionsModule.conditions)
  • Myelodysplastic Syndrome (protocolSection.conditionsModule.conditions)
  • Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis (protocolSection.conditionsModule.conditions)
  • Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable (protocolSection.conditionsModule.conditions)
  • Myeloid Neoplasm (protocolSection.conditionsModule.conditions)
  • Myeloproliferative Neoplasm (protocolSection.conditionsModule.conditions)
  • Myeloproliferative Neoplasm, Unclassifiable (protocolSection.conditionsModule.conditions)
  • Overt Primary Myelofibrosis (protocolSection.conditionsModule.conditions)
  • Polycythemia Vera (protocolSection.conditionsModule.conditions)
  • Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase (protocolSection.conditionsModule.conditions)
  • Prefibrotic/Early Primary Myelofibrosis (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.